17 news items
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
SAVA
5 Apr 24
and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers. Then, in August 2021, a Citizen
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
SAVA
31 Mar 24
and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers. Then, in August 2021, a Citizen
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
SAVA
29 Mar 24
or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
SAVA
28 Mar 24
or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
SAVA
27 Mar 24
with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers
uef4gnctunn3u0lj6ynmlroby8wdr9eyv8ddz5tk1098j 4p
AMLX
INMD
NYCB
25 Mar 24
the long-term safety and tolerability of simufilam 100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess
t2n8vm5eb0keocu0khzti0sosk3nv60x5nlz7swa3xuyuidkafz4vu0e7
SAVA
25 Mar 24
Phase 3 trials of simufilam in Alzheimer's disease. This DSMB only reviews patient safety. It does not assess drug efficacy
rfgg7upx5yktf0rxdziopq3xneeifncbeq32hwz
SAVA
23 Mar 24
disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers. Then, in August 2021
emwd cg9e8xmyglqfp9jpy1e5xtpxwiwcvvgnyizznjjgn8lyw1g3ikpn
AMLX
INMD
NYCB
21 Mar 24
100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes
4gllg xei1i4
SAVA
21 Mar 24
-term safety and tolerability of simufilam 100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory
2ok9wp2d56bcodbmn1vgqcyiyl0rpu ptvbvcf9f9hssp
AMLX
INMD
NYCB
17 Mar 24
and tolerability of simufilam 100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints
fxw9t11cl6ynkcwo0qav860 riais15jnsh6mu90ha
SAVA
15 Mar 24
the long-term safety and tolerability of simufilam 100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess
wgeucgk52f68c3tw4rsa7 845me3woesbfm89c6acku1bb1mahh1h
SAVA
14 Mar 24
daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition
7rh43161sy7rzr6aklvianbu
SAVA
13 Mar 24
-term safety and tolerability of simufilam 100 mg twice daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory
10peasca6plr2rq4brjtt9
AMLX
CART
EAF
12 Mar 24
daily for 12 or more months in patients with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition
2va59msjtryj86kunzv
AMLX
CART
EAF
8 Mar 24
with Alzheimer's disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers
2qepgeda btrp8sznmyywm
SAVA
7 Mar 24
disease and to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers. Then, in August 2021
- Prev
- 1
- Next